Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42.

Mythreye K, Blobe GC.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8221-6. doi: 10.1073/pnas.0812879106. Epub 2009 May 1.


The type III TGFbeta receptor regulates directional migration: new tricks for an old dog.

Mythreye K, Blobe GC.

Cell Cycle. 2009 Oct 1;8(19):3069-70. Epub 2009 Oct 8.


The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

You HJ, How T, Blobe GC.

Carcinogenesis. 2009 Aug;30(8):1281-7. doi: 10.1093/carcin/bgp071. Epub 2009 Mar 26.


TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells.

Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC.

Oncogene. 2013 Mar 14;32(11):1416-27. doi: 10.1038/onc.2012.157. Epub 2012 May 7.


The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Lee JD, Hempel N, Lee NY, Blobe GC.

Carcinogenesis. 2010 Feb;31(2):175-83. doi: 10.1093/carcin/bgp271. Epub 2009 Dec 2.


The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.

Lee NY, Kirkbride KC, Sheu RD, Blobe GC.

Mol Biol Cell. 2009 Oct;20(20):4362-70. doi: 10.1091/mbc.E09-07-0539. Epub 2009 Sep 2.


Roles for the type III TGF-beta receptor in human cancer.

Gatza CE, Oh SY, Blobe GC.

Cell Signal. 2010 Aug;22(8):1163-74. doi: 10.1016/j.cellsig.2010.01.016. Epub 2010 Feb 12. Review.


The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells.

Oh SY, Knelson EH, Blobe GC, Mythreye K.

Biochem J. 2013 Aug 15;454(1):79-89. doi: 10.1042/BJ20121701.


The type III TGF-beta receptor suppresses breast cancer progression.

Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC.

J Clin Invest. 2007 Jan;117(1):206-17. Epub 2006 Dec 7.


The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.

Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.

Neoplasia. 2014 Jun;16(6):489-500. doi: 10.1016/j.neo.2014.05.008.


Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.


Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC.

Carcinogenesis. 2008 May;29(5):905-12. doi: 10.1093/carcin/bgn049. Epub 2008 Feb 24.


TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.

Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC.

Carcinogenesis. 2008 Mar;29(3):528-35. doi: 10.1093/carcin/bgm289. Epub 2008 Jan 3.


Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.

Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC.

Mol Biol Cell. 2014 Aug 15;25(16):2320-32. doi: 10.1091/mbc.E13-09-0524. Epub 2014 Jun 25.


The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC.

Cancer Res. 2007 Feb 1;67(3):1090-8.


Type III TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling.

Xu D, Li D, Lu Z, Dong X, Wang X.

Oncol Rep. 2016 Jan;35(1):267-74. doi: 10.3892/or.2015.4390. Epub 2015 Nov 3.


The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.

Lambert KE, Huang H, Mythreye K, Blobe GC.

Mol Biol Cell. 2011 May;22(9):1463-72. doi: 10.1091/mbc.E10-11-0877. Epub 2011 Mar 16.


Loss of betaglycan expression in ovarian cancer: role in motility and invasion.

Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC.

Cancer Res. 2007 Jun 1;67(11):5231-8. Epub 2007 May 23.

Supplemental Content

Support Center